Abstract: A composition suitable for the treatment and/or prophylaxis of a coccidiosis induced condition in poultry. The composition comprises guanidinoacetic acid, a salt of guanidinoacetic acid, or a mixture thereof. The coccidiosis may be caused by Eimeria spp. or Clostridium perfringens, and the coccidiosis induced condition may be bacterial enteritis, necrotic enteritis, diarrhea, or lesion.

Abstract: The present invention is related to a method of determining suitability of at least one Chinese Hamster Ovary (CHO) test cell line for optimal heterologous protein production, the method comprising: (a) determining a test methylation profile from genomic material obtained from the CHO test cell line; and (b) comparing the test methylation profile obtained from (a) with a reference methylation profile, wherein the reference methylation profile comprises the methylation status of more than one CpG site from at least one CHO reference cell line that displays at least one phenotype of interest for optimal heterologous protein production, wherein a significant similarity in the test methylation profile of (a) compared to the reference methylation profile, is indicative of the CHO test cell line being suitable for optimal heterologous protein production and wherein the test methylation profile and reference methylation profile are from CpG sites from the CHO cell genome and are determined using DNA methylation-

Abstract: The present invention relates to a method of certifying a test animal-derived product sample, the method comprising the steps of: (a) determining a test methylation profile of one or more pre-selected methylation sites within the genomic material obtained from the test animal derived product sample; and (b) comparing the test methylation profile obtained from (a) with a reference methylation profile obtained from a control animal of the same biological taxon of the test animal from which the product sample is derived from, where the control animal is bred under a known distinct type of animal husbandry; wherein a significant similarity in the test methylation profile of (a) compared to the reference methylation profile from the control animal, is indicative of the test animal having been bred under the same distinct type of animal husbandry as the control animal and the test animal-derived product is certified so; wherein a difference in the test methylation profile of (a) compared to the reference methyla

Abstract: A method of determining if a terrestrial test animal and/or test animal from which a product is derived has been treated and/or is currently undergoing treatment with at least one antibiotic and/or veterinary chemical includes: (a) determining a test methylation profile from genomic material contained in a biological sample obtained from the test animal and/or the animal-derived product; and (b) comparing the test methylation profile obtained from (a) with a reference methylation profile obtained from a control animal of the same biological taxon of the test animal, where the control animal was not treated and/or is not currently undergoing treatment with at least one antibiotic and/or veterinary chemical, wherein a difference in the test methylation profile of (a) compared to the reference methylation profile from the control animal is indicative of the test animal having been treated and/or is currently undergoing treatment with at least one antibiotic and/or veterinary chemical.

Abstract: A DNA methylation-based array includes at least: a first plurality of distinct locations, each location having at least one probe molecule comprising a nucleic acid sequence complementary to a CpG site from a first plurality of CpG sites of a first animal species; and a second plurality of distinct locations, each location having at least one probe molecule comprising a nucleic acid sequence complementary to a CpG site from a second plurality of CpG sites of a second animal species, wherein the first and second animal species are each independently selected from the group consisting of virus, mammals, birds and aquatic animals, and wherein the first plurality of CpG sites comprises at least 1000 CpG sites of the first animal species; and the second plurality of CpG sites comprises at least 1000 CpG sites of the second animal species.

Abstract: A method of determining if an aquatic test animal and/or test animal from which a product is derived has been treated and/or is currently undergoing treatment with at least one antibiotic and/or veterinary chemical includes: (a) determining a test methylation profile from genomic material contained in a biological sample obtained from the test animal and/or animal-derived product; and (b) comparing the test methylation profile obtained from (a) with a reference methylation profile obtained from a control animal of the same biological taxon of the test animal, where the control animal was not treated and/or is not currently undergoing treatment with at least one antibiotic and/or veterinary chemical, wherein a difference in the test methylation profile of (a) compared to the reference methylation profile from the control animal is indicative of the test animal having been treated and/or is currently undergoing treatment with at least one antibiotic and/or veterinary chemical.

Abstract: The present invention is related to a method of detecting DNA methylation and/or determining a test methylation profile from genomic material contained in a biological sample obtained from a test animal-derived product, the method comprises the step of: contacting a genomic material sample from the test animal-derived product with a DNA methylation array specific for species of the test animal, wherein the test animal is a monogastric livestock.

Abstract: An in vitro method for predicting the biological age of a subject includes: (a) bisulfite treatment of genomic DNA extracted from a biological sample obtained from the subject; (b) amplifying the bisulfite treated genomic DNA from step (a) with specific primers that target at least two Low Methylated Region (LMR) in the genomic DNA from (a) to obtain at least one PCR product; (c) measuring the methylation level of CpG sites in the PCR product of step (b); and (d) determining the biological age of the subject with a statistical prediction algorithm, wherein the statistical prediction algorithm is applied to the measured methylation level to determine the epigenetic age of the subject; wherein the subject is from the Galliformes family; and wherein at least three LMRs are amplified in step (b); and with a proviso that the CpG sites associated with single nucleotide polymorphisms are not considered.

Abstract: The invention provides a method for classifying the gut inflammation status of an avian subject or of a group of avian subjects to be tested, the method comprising the comparison of the average methylation levels within a panel of pre-selected LMRs in the genomic DNA isolated from gut sample material deriving from the individual avian subject or of the group of avian subjects to be tested with the average methylation levels of the same panel of LMRs in the genomic DNA pertaining to one or more reference samples having a negative gut inflammation status.

Abstract: The invention provides a method of establishing a chicken methylation clock comprising: (a) determining the methylation ratio and the read coverage of the genomic CpG sites of an age-correlated training sample of a specific chicken tissue; (b) defining a set of CpG sites having reliable methylation ratios in all training samples of step (a) using a cutoff value; and (c) performing a penalized regression using the methylation ratios of step (b) as input and the age correlated to the training sample as dependent variable, by applying a penalized regression model; thereby obtaining a set of CpG sites with corresponding weighting factors and intercept of the linear model equation as parameters defining the chicken methylation clock.

Abstract: The current invention concerns a new B. subtilis strain with strong inhibition of C. perfringens and its use as a probiotic.

Abstract: The current invention concerns a new B. licheniformis strain with strong inhibition of C. perfringens and its use as probiotic.

Abstract: The current invention concerns a new B. subtilis strain with strong inhibition of C. perfringens and its use as a probiotic.

Abstract: The present invention is directed to a transgenic probiotic microorganism genetically engineered to express and secrete cystatin, wherein said cystatin is preferably comprises or consists of: an amino acid sequence with SEQ ID NO. 1 to 3; and an amino acid sequence that is at least 70% identical, preferably at least 80% identical, more preferably at least 90% identical and most preferably at least 99% identical to an amino acid sequence with SEQ ID NO. 1 to 3, and to its use for treatment of gastrointestinal inflammatory diseases.